A previous study in colorectal cancer showed that SLC2A3 could regulate the epithelial–mesenchymal transition (EMT) classical pathway and PD-L1-mediated immune responses (Gao et al., 2021), which was consistent with our research results. This evidence concerns the gene SLC2A3 and colorectal cancer.